Press Release Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates 4 hours ago
Press Release Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma Aug 10